How are the Premier's Awards helping cancer researchers?
2 May 2019
The Premier’s Awards not only recognise the state’s top cancer researchers but also propels their work to greater heights.
Hear from the 2017 winners and find out how it is influencing their work:
Melanoma Translational Research Team
– Wildfire Highly Cited Publication Award
The award is allowing Professor Rizos’ team to extend their research into regulating melanoma gene expression and its role in the response of melanoma to immunotherapy.
Melanoma Institute Australia
– Excellence in Translational Cancer Research Award
The award is supporting a plethora of Melanoma Institute Australia research projects that made headlines around the world. These include discovering the specific mechanisms behind immune-mediated equilibrium
Professor Scolyer and Professor Long won major awards at the 2018
– Outstanding Cancer Researcher of the Year Award
Professor Kefford’s is commissioning a tailor-made, melanoma-specific gene mutation panel for DNA sequencing machinery in their laboratory. The award is enabling his team to extend their research into regulating melanoma gene expression and its role in the response of melanoma to immunotherapy.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.